Teva Pharmaceutical Industries Limited (NYSE:TEVA) was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating in a report issued on Friday.

TEVA has been the subject of a number of other reports. Credit Suisse Group set a $39.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “buy” rating in a report on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the stock a “hold” rating in a report on Thursday, June 22nd. Vetr raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target for the company in a research note on Monday, July 24th. Zacks Investment Research raised shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Four investment analysts have rated the stock with a sell rating, nineteen have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $35.06.

Teva Pharmaceutical Industries Limited (TEVA) opened at 15.93 on Friday. Teva Pharmaceutical Industries Limited has a 52-week low of $15.72 and a 52-week high of $52.66. The company’s market cap is $16.18 billion. The company’s 50 day moving average price is $25.37 and its 200 day moving average price is $30.35.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by $0.07. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company had revenue of $5.69 billion for the quarter, compared to the consensus estimate of $5.72 billion. During the same period in the prior year, the firm posted $1.25 earnings per share. The business’s revenue was up 12.9% on a year-over-year basis. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The legal version of this news story can be read at https://www.watchlistnews.com/teva-pharmaceutical-industries-limited-teva-rating-lowered-to-d-at-thestreet/1529494.html.

A number of large investors have recently made changes to their positions in TEVA. Capital Research Global Investors boosted its stake in shares of Teva Pharmaceutical Industries Limited by 13.8% in the second quarter. Capital Research Global Investors now owns 76,325,059 shares of the company’s stock worth $2,535,518,000 after buying an additional 9,260,426 shares during the period. Franklin Resources Inc. boosted its stake in shares of Teva Pharmaceutical Industries Limited by 11.1% in the second quarter. Franklin Resources Inc. now owns 66,796,897 shares of the company’s stock worth $2,218,958,000 after buying an additional 6,685,844 shares during the period. FMR LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 16.7% in the second quarter. FMR LLC now owns 42,844,979 shares of the company’s stock worth $1,423,310,000 after buying an additional 6,115,853 shares during the period. Northern Cross LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited by 14.0% in the second quarter. Northern Cross LLC now owns 17,795,579 shares of the company’s stock worth $591,169,000 after buying an additional 2,184,172 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Teva Pharmaceutical Industries Limited by 2.5% in the second quarter. Nordea Investment Management AB now owns 12,884,810 shares of the company’s stock worth $428,033,000 after buying an additional 311,894 shares during the period. Institutional investors and hedge funds own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with Analyst Ratings Network's FREE daily email newsletter.